What is it about?
This article explores the evidence about reliability of apoptosis markers in AML prognosis. It also challenges the utility and feasibility of use of anti-Bcl 2 chemotherapy.
Featured Image
Why is it important?
Acute myeloid leukemia is a type of blood cancer that has high mortality despite treatment. This article explores the prognostic value of markers related to programmed cell death in this disease and raises questions about the utility of targeting those markers for therapeutic purposes.
Perspectives
This is a data-rich scholarly work that is an important piece of evidence in the field.
Dr Nasir Ali Afsar
Jinnah Medical & Dental College Karachi; Alfaisal University Riyadh.
Read the Original
This page is a summary of: Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy?, Cancer Management and Research, March 2018, Dove Medical Press,
DOI: 10.2147/cmar.s154608.
You can read the full text:
Contributors
The following have contributed to this page
